TAKEDA PHARMACEUTICAL CO LTDTAK

Market cap

P/E ratio

	Mar 31, 2019	Mar 31, 2020	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024
Revenue	2,097,224	-	3,197,812	3,569,006	4,027,478	4,263,762
Cost of sales	659,690	-	994,308	1,106,846	1,244,072	1,426,678
Selling, general and administrative expenses	717,599	-	875,663	886,361	997,309	1,053,819
Research and development expenses	368,298	-	455,833	526,087	633,325	729,924
Amortization and impairment losses on intangible assets associated with products	203,372	-	421,864	472,915	542,443	652,117
Other income	159,863	-	318,020	43,123	25,424	19,379
Other operating expenses	103,159	-	258,895	159,075	145,247	206,527
Operating profit	204,969	-	509,269	460,844	490,505	214,075
Finance income	16,843	-	105,521	23,700	62,913	52,093
Finance expenses	83,289	-	248,631	166,607	169,698	219,850
Share of profit (loss) of investments accounted for using the equity method	-43,627	-	76	-15,367	-8,630	6,473
Profit before tax	94,896	-	366,235	302,571	375,090	52,791
Income tax (expenses) benefit	-14,118	-	-9,936	72,405	58,052	-91,406
Net profit for the year	109,014	44,290	376,171	230,166	317,038	144,197
Owners of the Company	109,126	-	376,005	230,059	317,017	144,067
Non-controlling interests	-112	-	166	107	21	130
Net profit for the year	109,014	44,290	376,171	230,166	317,038	144,197
Basic earnings (loss) per share	113.5	-	240.72	147.14	204.29	92.09
Diluted earnings (loss) per share	112.86	-	238.96	145.87	201.94	91.16